stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aintel earnings have message for amd and nvidia ‘bring it on’ aamazon’s freespending ways hit earnings but don’t expect a shift to thrift amerck q januviajanumet revenue  bln vs  bln factset consensus  bln amerck q keytruda sales  mln vs  mln a year ago factset consensus  mln amerck raises  revenue outlook to  bln bln from  bln bln amerck affirms  adj eps outlook of  amerck q revenue  bln vs  bln factset consensus  bln amerck q adj eps  factset consensus  cents amerck q eps  cents vs  cents a year ago arussia retaliates to new sanctions by telling us to cut diplomats aget ready for the lessprofitable amazon that you used to know athis basic balanced index fund is beating the hedge fund averages arenault profit leaps but shares decline abelgiums inflation rate picks up pace agerman consumer prices rise faster than expected afrench economy expands  in the second quarter abig six leave border adjustment out of tax principles akids are training to be ceos and spies at these specialized summer camps aamericans are so uncomfortable asking for money that we’ve resorted to this instead aoil pauses ahead of us rig data but  weekly gain in sight loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aintel earnings have message for amd and nvidia ‘bring it on’ aamazon’s freespending ways hit earnings but don’t expect a shift to thrift amerck q januviajanumet revenue  bln vs  bln factset consensus  bln amerck q keytruda sales  mln vs  mln a year ago factset consensus  mln amerck raises  revenue outlook to  bln bln from  bln bln amerck affirms  adj eps outlook of  amerck q revenue  bln vs  bln factset consensus  bln amerck q adj eps  factset consensus  cents amerck q eps  cents vs  cents a year ago arussia retaliates to new sanctions by telling us to cut diplomats aget ready for the lessprofitable amazon that you used to know athis basic balanced index fund is beating the hedge fund averages arenault profit leaps but shares decline abelgiums inflation rate picks up pace agerman consumer prices rise faster than expected afrench economy expands  in the second quarter abig six leave border adjustment out of tax principles akids are training to be ceos and spies at these specialized summer camps aamericans are so uncomfortable asking for money that we’ve resorted to this instead aoil pauses ahead of us rig data but  weekly gain in sight loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  ﻿ prothena corporation plc prta position reduced by california public employees retirement system  markets daily daily ratings  news for prothena corporation plc complete the form below to receive the latest headlines and analysts recommendationsfor prothena corporation plc with our free daily email newsletter follow themarketsdaily the markets daily recent posts colony starwood homes sfr shares sold by california public employees retirement system jefferies group comments on navient corporation’s q  earnings navi pnc financial services group inc has  position in koppers holdings inc kop duluth holdings inc dlth stake reduced by pnc financial services group inc pnc financial services group inc has  stake in zynga inc znga california public employees retirement system has  million stake in oxford industries inc oxm prothena corporation plc prta position reduced by california public employees retirement system stephens inc ar has  million position in pnc financial services group inc the pnc california public employees retirement system has  million position in abaxis inc abax novartis ag vtxnovn pt set at chf  by deutsche bank ag sykes enterprises incorporated syke stake reduced by tiaa cref investment management llc tiaa cref investment management llc decreases position in simpson manufacturing company inc ssd tri pointe group inc tph position decreased by tiaa cref investment management llc integer holdings co itgr stake lowered by tiaa cref investment management llc california public employees retirement system lowers position in premier inc pinc usana health sciences inc usna shares bought by teachers advisors llc keysight technologies inc keys stake raised by teachers advisors llc time inc time shares bought by teachers advisors llc rowan companies plc rdc stake decreased by teachers advisors llc ford motor company f position reduced by citizens financial group inc ri prothena corporation plc prta position reduced by california public employees retirement system posted by sarita garza on jul st   no comments california public employees retirement system decreased its stake in shares of prothena corporation plc nasdaqprta by  during the first quarter according to its most recent filing with the securities and exchange commission the firm owned  shares of the biotechnology company’s stock after selling  shares during the period california public employees retirement system owned  of prothena corporation plc worth  at the end of the most recent quarter a number of other hedge funds have also modified their holdings of the stock fmr llc increased its stake in shares of prothena corporation plc by  in the first quarter fmr llc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter norges bank acquired a new stake in shares of prothena corporation plc during the fourth quarter valued at approximately  wellington management group llp increased its stake in shares of prothena corporation plc by  in the first quarter wellington management group llp now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter alliancebernstein lp increased its stake in shares of prothena corporation plc by  in the first quarter alliancebernstein lp now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter finally swiss national bank increased its stake in shares of prothena corporation plc by  in the first quarter swiss national bank now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter get prothena corporation plc alerts prothena corporation plc nasdaq prta opened at  on friday prothena corporation plc has a month low of  and a month high of  the stock’s  day moving average price is  and its  day moving average price is  the company’s market capitalization is  billion prothena corporation plc nasdaqprta last announced its quarterly earnings data on tuesday may th the biotechnology company reported  earnings per share for the quarter beating analysts’ consensus estimates of  by  the firm had revenue of  million for the quarter compared to analyst estimates of  million prothena corporation plc had a negative net margin of  and a negative return on equity of  the business’s quarterly revenue was down  compared to the same quarter last year during the same period in the previous year the company earned  earnings per share on average equities analysts anticipate that prothena corporation plc will post  eps for the current fiscal year illegal activity notice “prothena corporation plc prta position reduced by california public employees retirement system” was originally published by markets daily and is the property of of markets daily if you are viewing this piece on another publication it was copied illegally and republished in violation of us and international trademark  copyright legislation the original version of this piece can be read at httpswwwthemarketsdailycomprothenacorporationplcprtapositionreducedbycaliforniapublicemployeesretirementsystemhtml prta has been the topic of several recent analyst reports zacks investment research upgraded prothena corporation plc from a “hold” rating to a “buy” rating and set a  target price on the stock in a research note on tuesday april th oppenheimer holdings inc set a  target price on prothena corporation plc and gave the company a “buy” rating in a research note on thursday may th valuengine upgraded prothena corporation plc from a “strong sell” rating to a “sell” rating in a research note on friday june nd piper jaffray companies reiterated a “buy” rating on shares of prothena corporation plc in a research note on tuesday may th finally cantor fitzgerald initiated coverage on prothena corporation plc in a research note on wednesday april th they set an “overweight” rating and a  target price on the stock two research analysts have rated the stock with a hold rating thirteen have issued a buy rating and one has assigned a strong buy rating to the company prothena corporation plc presently has an average rating of “buy” and a consensus price target of  in other news director dennis j selkoe sold  shares of the business’s stock in a transaction on friday july th the shares were sold at an average price of  for a total transaction of  following the sale the director now directly owns  shares of the company’s stock valued at  the sale was disclosed in a filing with the securities  exchange commission which is available through this link also insider karin l walker sold  shares of the business’s stock in a transaction on monday july th the shares were sold at an average price of  for a total transaction of  following the sale the insider now directly owns  shares in the company valued at  the disclosure for this sale can be found here  of the stock is owned by insiders about prothena corporation plc prothena corporation public limited company is a global biotechnology company the company is focused on the discovery development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion the company’s clinical pipeline of antibodybased product candidates targets a range of indications including amyloid lightchain al amyloidosis neod parkinson’s disease and other related synucleinopathies prx and inflammatory diseases including psoriasis and psoriatic arthritis prx and attr amyloidosis prx receive news  ratings for prothena corporation plc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for prothena corporation plc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aintel earnings have message for amd and nvidia ‘bring it on’ aamazon’s freespending ways hit earnings but don’t expect a shift to thrift amerck q januviajanumet revenue  bln vs  bln factset consensus  bln amerck q keytruda sales  mln vs  mln a year ago factset consensus  mln amerck raises  revenue outlook to  bln bln from  bln bln amerck affirms  adj eps outlook of  amerck q revenue  bln vs  bln factset consensus  bln amerck q adj eps  factset consensus  cents amerck q eps  cents vs  cents a year ago arussia retaliates to new sanctions by telling us to cut diplomats aget ready for the lessprofitable amazon that you used to know athis basic balanced index fund is beating the hedge fund averages arenault profit leaps but shares decline abelgiums inflation rate picks up pace agerman consumer prices rise faster than expected afrench economy expands  in the second quarter abig six leave border adjustment out of tax principles akids are training to be ceos and spies at these specialized summer camps aamericans are so uncomfortable asking for money that we’ve resorted to this instead aoil pauses ahead of us rig data but  weekly gain in sight loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  prta stock price  prothena corp plc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y djia f    sp f    nasdaq f    gold    silver    crude oil    sp  movers adp  tsco  vz  orly  ca  jci  ffiv  xl  latest newsall times eastern a updated intel earnings have message for amd and nvidia ‘bring it on’ a updated amazon’s freespending ways hit earnings but don’t expect a shift to thrift a merck q januviajanumet revenue  bln vs  bln factset consensus  bln a merck q keytruda sales  mln vs  mln a year ago factset consensus  mln a merck raises  revenue outlook to  bln bln from  bln bln a merck affirms  adj eps outlook of  a merck q revenue  bln vs  bln factset consensus  bln a merck q adj eps  factset consensus  cents a merck q eps  cents vs  cents a year ago a updated russia retaliates to new sanctions by telling us to cut diplomats to be replaced home investing quotes stocks united states prta overview compare quotes stock screener earnings calendar sectors nasdaq prta us nasdaq join td ameritrade find a broker prothena corp plc watchlist createprtaalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones charting the sp ’s bullishleaning holding pattern ahead of the fed sep   at  pm et by michael ashbaugh charting the sp ’s bullishleaning holding pattern ahead of the fed sep   at  pm et by michael ashbaugh prothena started at overweight with  stock price target at barclays may   at  am et by tomi kilgore opinion dozens of biotech companies are ‘free’ for investors’ taking feb   at  am et by michael brush charting a gardenvariety market pullback nov   at  pm et by michael ashbaugh charting a gardenvariety market pullback nov   at  am et by michael ashbaugh sp  holds major support preserving the bull trend jun   at  pm et by michael ashbaugh sp  holds major support preserving the bull trend jun   at  am et by michael ashbaugh  stocks to watch mar   at  pm et by harry boxer corrected prothena shares jump on parkinsons drug study data mar   at  pm et by wallace witkowski nike shares rise after profit beat revenue miss mar   at  pm et by wallace witkowski roche prothena ink pact on parkinsons treatments dec   at  am et stocks to watch macerich darden restaurants tiffany mar   at  am et on the wall street journal prothena reports positive results for parkinson’s treatment in earlystage study mar   at  pm et on the wall street journal rbc is in the lead going into the turn jul   at  am et on barrons prothena revved up by roche deal dec   at  pm et on barrons stocks to watch lululemon ciena facebook dec   at  am et on the wall street journal cfo moves par technology ocz technology group prothena mar   at  pm et on the wall street journal recent news other news press releases prothena announces midstage initiation of parkinsons drug prothena announces midstage initiation of parkinsons drug jul   at  pm et on seeking alpha muddy waters shorts prothena on doubts of drug candidates efficacy muddy waters shorts prothena on doubts of drug candidates efficacy jun   at  pm et on benzingacom prothena slumps  on muddy waters short position doubts efficacy of lead product candidate prothena slumps  on muddy waters short position doubts efficacy of lead product candidate jun   at  am et on seeking alpha prothena prta down  since earnings report can it rebound prothena prta reported earnings  days ago whats next for the stock we take a look at earnings estimates for some clues jun   at  am et on zackscom premarket analyst action  healthcare premarket analyst action  healthcare may   at  am et on seeking alpha prothena prta q loss narrower than expected updates view prothena corporation plc prta reported a loss of  cents per share in the first quarter of  wider than the yearago loss of  cents may   at  pm et on zackscom safety concerns with ionis inotersen makes prothena worth a look  piper safety concerns with ionis inotersen makes prothena worth a look  piper may   at  pm et on seeking alpha notable earnings after tuesday’s close notable earnings after tuesday’s close may   at  pm et on seeking alpha what to expect from prothena prta this earnings season apr   at  pm et on zackscom prothena prta clinical results from phase b mad study of prxrg in patients with parkinsons disease  slideshow apr   at  pm et on seeking alpha why is prothena prta up  since the last earnings report mar   at  am et on zackscom premarket analyst action  healthcare mar   at  am et on seeking alpha k prothena corp plc feb   at  am et on edgar online  edg  q k prothena prta reports widerthanexpected loss in q feb   at  pm et on zackscom prothenas prta ceo gene kinney on q  results  earnings call transcript feb   at  am et on seeking alpha the zacks analyst blog highlights incyte prothena acorda therapeutics and axovant sciences feb   at  am et on zackscom drug stocks earnings slated for feb  incy prta  more feb   at  am et on zackscom can prothena prta pull a surprise this earnings season feb   at  pm et on zackscom prothena grabbing at chunk of  billion io market ceo exclusive jan   at  pm et on investors business daily  healthcare stocks that will cripple your portfolio jan   at  pm et on investorplacecom prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinsons disease prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinsons disease jul   at  pm et on globe newswire prothena announces appointment of wagner zago phd as chief scientific officer prothena announces appointment of wagner zago phd as chief scientific officer jun   at  am et on globenewswire prothena announces appointment of wagner zago phd as chief scientific officer prothena announces appointment of wagner zago phd as chief scientific officer jun   at  am et on globe newswire prothena announces appointment of sarah noonberg md phd as chief medical officer prothena announces appointment of sarah noonberg md phd as chief medical officer may   at  pm et on globenewswire prothena announces appointment of sarah noonberg md phd as chief medical officer prothena announces appointment of sarah noonberg md phd as chief medical officer may   at  pm et on globe newswire prothena reports first quarter  financial results and provides rd update prothena reports first quarter  financial results and provides rd update may   at  pm et on globe newswire prothena to report first quarter  financial results on may  prothena to report first quarter  financial results on may  may   at  pm et on globenewswire prothena to report first quarter  financial results on may  prothena to report first quarter  financial results on may  may   at  pm et on globe newswire prothena to participate in the deutsche bank nd annual health care conference apr   at  pm et on globe newswire prothena to participate in the deutsche bank nd annual health care conference apr   at  pm et on globenewswire clinical results presented from prothenas phase b study of prxrg demonstrating robust antibody cns penetration and significant reduction of free serum alphasynuclein in patients with parkinsons disease apr   at  am et on globenewswire prothena corporation plc  press release apr   at  am et on globe newswire results for prothenas phase b multiple ascending dose study of prx mar   at  pm et on globe newswire results for prothenas phase b multiple ascending dose study of prxrg in patients with parkinsons disease to be presented at the th international conference on alzheimers and parkinsons diseases mar   at  pm et on globenewswire learn how to target a  return on avexis inc or get optiontrade ideas on ionis pharmaceuticals the medicines co prothena and tesaro inc or any stock you choose mar   at  am et on pr newswire  prf prothena announces pricing of public offering of  ordinary shares mar   at  am et on globe newswire prothena announces pricing of public offering of  ordinary shares mar   at  am et on globenewswire prothena corporation plc  prothena announces public offering of ordinary shares mar   at  pm et on globe newswire prothena announces public offering of ordinary shares mar   at  pm et on globenewswire prothena reports fourth quarter and full year  financial results and provides financial guidance and rd update feb   at  pm et on globenewswire prothena corp plc prothena corp plc is a clinical stage biotechnology company which engages in the discovery development and commercialization of novel antibodies its antibodybased product candidates target a number of potential indications including al amyloidosis neod parkinsons disease and related synucleinopathies prx inflammatory diseases including psoriasis psoriatic arthritis prx and attr amyloidosis prx the company was founded on december   and is headquartered in dun laoghaire ireland see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top initiations may   at  am et on benzingacom heres why theres been a rush of biotech offerings jan   at  am et on benzingacom ubs biotech will continue to outperform in  sep   at  pm et on benzingacom competitors name chg  market cap shire plc adr  b alnylam pharmaceuticals inc  b amarin corp plc adr  b alkermes plc  b mallinckrodt plc  b competitor data provided by partner content trending tickers powered by amzn  spy  uvxy  aapl  fslr  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience analyst coverage  prothena corporation plc analyst coverage prothena corporation plc is covered by the following analysts analyst coverage firm analyst contact information bank of america merrill lynch tazeen ahmad   barclays geoff meacham phd   btig robert bert hazlett   cantor fitzgerald william tanner phd   deutsche bank andrew peters   jefferies michael j yee   nomura  instinet christopher marai phd   oppenheimer jay olson cfa   suntrust robinson humphrey yun zhong phd   ubs jeff hung   wedbush securities david m nierengarten phd   please note that any opinions estimates or forecasts regarding prothena corporation plcs performance made by these analysts are theirs alone and do not represent opinions forecasts or predictions of prothena corporation plc or its management prothena corporation plc does not by its reference above or distribution imply its endorsement of or concurrence with such information conclusions or recommendations facebook google linkedin twitter email rss close scroll to top committee composition  prothena corporation plc committee composition display all bios board of directors audit compensation nominating and corporate governance lars g ekman md phd lars g ekman md phd chairman of the board dr ekman is an executive partner at sofinnova ventures inc a position he has held since  dr ekman is also chairman of the board of sophiris bio inc where he also served as president from  to  he also is chairman of the board of amarin corporation plc serves as a director of spark therapeutics inc and ultragenyx pharmaceutical inc served as a director of ocera therapeutics inc from  to  and served as a director of intermune inc from  to  dr ekman cofounded cebix incorporated where he served as chief executive officer from  to  he was president of research  development at elan corporation plc from  to  where he also served as a director from  to  from  to  dr ekman was executive vice president research  development at schwarz pharma ag prior to that he held various senior positions at pharmacia corporation dr ekman is a boardcertified surgeon with a phd in experimental biology and has held several clinical and academic positions in both the united states and europe he earned his phd and md from the university of gothenburg sweden dr ekman has served as chairman of our board since   close     richard t collier richard t collier director mr collier is an adjunct professor of law at the temple university beasley school of law in philadelphia where he has taught drug and medical device law since  from  to  mr collier also served as executive vice president and general counsel of elan corporation plc prior to that he served as senior vice president and general counsel of rhonepoulenc rorer inc pharmacia  upjohn company and pharmacia corporation mr collier also practiced law at two leading philadelphiabased law firms and served with the us federal trade commission in washington dc and the us department of justice in philadelphia mr collier earned both his ba and his jd from temple university he has served on our board since      close   shane m cooke shane m cooke director mr cooke is president of alkermes plc a position he has held since  prior to that he served as head of elan drug technologies and executive vice president of elan corporation plc from  to  where he also served as chief financial officer from  to  and as a director from  to  mr cooke has also held a number of senior positions in finance in the banking and aviation industries he is also a director of endo international plc mr cooke earned his bachelor of commerce and master of accounting degrees from university college dublin ireland and is a chartered accountant he has served on our board since      close     anders o härfstrand md phd anders o härfstrand md phd director dr härfstrand is chairman of härfstrand consulting ag which he founded in  he has over  years of experience in the pharmaceutical and biotechnology industries most recently dr härfstrand served as chief executive officer of bbb therapeutics bv from  to  prior to that he was president and chief executive officer europe of makhteshim agan industries ltd from  to  president and chief executive officer of humabs biomed sa from  to  and chief executive officer of nitec pharma ag from  to  dr härfstrand also served in various executive and management roles at serono pfizer and pharmacia and in nonexecutive roles on a number of supervisory boards in europe he also serves as a director of karolinska development ab dr härfstrand earned his md and phd in neuropharmacology endocrinology from karolinska institute in sweden he has served on our board since    close     christopher s henney phd dsc christopher s henney phd dsc director christopher s henney phd dsc is chairman of the board of cascadian therapeutics inc formerly oncothyreon inc a biotechnology company where he also served as interim president and chief executive officer for part of   he is also vicechairman of the board of cyclacel pharmaceuticals inc and a member of the board of anthera pharmaceuticals inc from  to  dr henney served as chairman of the board and chief executive officer of dendreon corporation a biotechnology company that he cofounded he also cofounded and served as a director and in executive positions at both immunex corporation and icos corporation dr henney was also a director of mymetics corporation during  he is a  inductee to the biotechnology hall of fame dr henney earned his bsc in medical biochemistry his phd in experimental pathology and his dsc for contributions to the field of immunology from the university of birmingham england he has served on our board since    close   dennis j selkoe md dennis j selkoe md director dr selkoe is the vincent and stella coates professor of neurologic diseases at harvard medical school and codirector of the center for neurologic diseases at brigham and women’s hospital in boston positions he has held since  and  respectively he has served on the faculty at harvard medical school since  dr selkoe was the principal founding scientist and served as a director of athena neurosciences inc until it was acquired by elan corporation plc in  he has received numerous honors including the mathilde solowey award in the neurosciences nih the potamkin prize american academy of neurology the ah heineken prize for medicine the pioneer award and the lifetime achievement award alzheimer’s association the george c cotzias lecture of the american academy of neurology and the ulysses medal of university college dublin dr selkoe is a fellow of the american academy of neurology and of the american association for the advancement of science a member of the institute of medicine of the national academies and a director of the foundation for neurologic diseases he served as a director of elan from  to  dr selkoe earned his ba from columbia university and his md from the university of virginia he has served on our board since      close    chair of the board  chair  member facebook google linkedin twitter email rss close scroll to top financials  filings  prothena corporation plc financials  filings first quarter  financial results prothena reports first quarter  financial results and provides rd update form q proxy statements title view mar   html pdf xls add to briefcase file is in briefcase apr   html pdf xls add to briefcase file is in briefcase form k date filed view feb   html pdf xls xbrl add to briefcase file is in briefcase feb   html pdf xls xbrl add to briefcase file is in briefcase form q date filed view may   html pdf xls xbrl add to briefcase file is in briefcase nov   html pdf xls xbrl add to briefcase file is in briefcase  add pdf file to briefcase facebook google linkedin twitter email rss close scroll to top investment calculator  prothena corporation plc investment calculator initial invested amount i invested select shares or currency shares dollars usd on historic month january february march april may june july august september october november december historic day  historic year  calculate    calculate current value and shares since december   investment date original shares original value current shares current value percent return dec        adjustments there are no adjustments for your investment the investment calculator page and related information is provided by mergent a third party service prothena corporation plc does not maintain this page and is not responsible for the accuracy completeness or timeliness of the information the results are for illustrative purposes only and should not be relied on for investment purposes the timing and price of dividend reinvestments taxes commissions and other factors may affect the values shown please note that historical investment performance is not intended to indicate future performance facebook google linkedin twitter email rss close scroll to top ﻿ prothena corporation plc prta position reduced by california public employees retirement system  markets daily daily ratings  news for prothena corporation plc complete the form below to receive the latest headlines and analysts recommendationsfor prothena corporation plc with our free daily email newsletter follow themarketsdaily the markets daily recent posts colony starwood homes sfr shares sold by california public employees retirement system jefferies group comments on navient corporation’s q  earnings navi pnc financial services group inc has  position in koppers holdings inc kop duluth holdings inc dlth stake reduced by pnc financial services group inc pnc financial services group inc has  stake in zynga inc znga california public employees retirement system has  million stake in oxford industries inc oxm prothena corporation plc prta position reduced by california public employees retirement system stephens inc ar has  million position in pnc financial services group inc the pnc california public employees retirement system has  million position in abaxis inc abax novartis ag vtxnovn pt set at chf  by deutsche bank ag sykes enterprises incorporated syke stake reduced by tiaa cref investment management llc tiaa cref investment management llc decreases position in simpson manufacturing company inc ssd tri pointe group inc tph position decreased by tiaa cref investment management llc integer holdings co itgr stake lowered by tiaa cref investment management llc california public employees retirement system lowers position in premier inc pinc usana health sciences inc usna shares bought by teachers advisors llc keysight technologies inc keys stake raised by teachers advisors llc time inc time shares bought by teachers advisors llc rowan companies plc rdc stake decreased by teachers advisors llc ford motor company f position reduced by citizens financial group inc ri prothena corporation plc prta position reduced by california public employees retirement system posted by sarita garza on jul st   no comments california public employees retirement system decreased its stake in shares of prothena corporation plc nasdaqprta by  during the first quarter according to its most recent filing with the securities and exchange commission the firm owned  shares of the biotechnology company’s stock after selling  shares during the period california public employees retirement system owned  of prothena corporation plc worth  at the end of the most recent quarter a number of other hedge funds have also modified their holdings of the stock fmr llc increased its stake in shares of prothena corporation plc by  in the first quarter fmr llc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter norges bank acquired a new stake in shares of prothena corporation plc during the fourth quarter valued at approximately  wellington management group llp increased its stake in shares of prothena corporation plc by  in the first quarter wellington management group llp now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter alliancebernstein lp increased its stake in shares of prothena corporation plc by  in the first quarter alliancebernstein lp now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter finally swiss national bank increased its stake in shares of prothena corporation plc by  in the first quarter swiss national bank now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter get prothena corporation plc alerts prothena corporation plc nasdaq prta opened at  on friday prothena corporation plc has a month low of  and a month high of  the stock’s  day moving average price is  and its  day moving average price is  the company’s market capitalization is  billion prothena corporation plc nasdaqprta last announced its quarterly earnings data on tuesday may th the biotechnology company reported  earnings per share for the quarter beating analysts’ consensus estimates of  by  the firm had revenue of  million for the quarter compared to analyst estimates of  million prothena corporation plc had a negative net margin of  and a negative return on equity of  the business’s quarterly revenue was down  compared to the same quarter last year during the same period in the previous year the company earned  earnings per share on average equities analysts anticipate that prothena corporation plc will post  eps for the current fiscal year illegal activity notice “prothena corporation plc prta position reduced by california public employees retirement system” was originally published by markets daily and is the property of of markets daily if you are viewing this piece on another publication it was copied illegally and republished in violation of us and international trademark  copyright legislation the original version of this piece can be read at httpswwwthemarketsdailycomprothenacorporationplcprtapositionreducedbycaliforniapublicemployeesretirementsystemhtml prta has been the topic of several recent analyst reports zacks investment research upgraded prothena corporation plc from a “hold” rating to a “buy” rating and set a  target price on the stock in a research note on tuesday april th oppenheimer holdings inc set a  target price on prothena corporation plc and gave the company a “buy” rating in a research note on thursday may th valuengine upgraded prothena corporation plc from a “strong sell” rating to a “sell” rating in a research note on friday june nd piper jaffray companies reiterated a “buy” rating on shares of prothena corporation plc in a research note on tuesday may th finally cantor fitzgerald initiated coverage on prothena corporation plc in a research note on wednesday april th they set an “overweight” rating and a  target price on the stock two research analysts have rated the stock with a hold rating thirteen have issued a buy rating and one has assigned a strong buy rating to the company prothena corporation plc presently has an average rating of “buy” and a consensus price target of  in other news director dennis j selkoe sold  shares of the business’s stock in a transaction on friday july th the shares were sold at an average price of  for a total transaction of  following the sale the director now directly owns  shares of the company’s stock valued at  the sale was disclosed in a filing with the securities  exchange commission which is available through this link also insider karin l walker sold  shares of the business’s stock in a transaction on monday july th the shares were sold at an average price of  for a total transaction of  following the sale the insider now directly owns  shares in the company valued at  the disclosure for this sale can be found here  of the stock is owned by insiders about prothena corporation plc prothena corporation public limited company is a global biotechnology company the company is focused on the discovery development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion the company’s clinical pipeline of antibodybased product candidates targets a range of indications including amyloid lightchain al amyloidosis neod parkinson’s disease and other related synucleinopathies prx and inflammatory diseases including psoriasis and psoriatic arthritis prx and attr amyloidosis prx receive news  ratings for prothena corporation plc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for prothena corporation plc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website key ratios  prothena corporation plc key ratios javascript will need to be enabled to view the content of this page data is currently unavailable price  volume recent price   week high   week low  average vol mil rtma beta share related items market cap mil  shares out mil float mil dividend information yield  annual dividend payout ratio ttm  financial strength quick ratio mrq current ratio mrq lt debtequity  mrq total debtequity  mrq valuation ratios priceearnings ttm pricesales ttm pricebook mrq pricecash flow ttm per share data earnings ttm  sales ttm  book value mrq  cash flow ttm  cash mrq  mgmt effectiveness return on equity ttm return on assets ttm return on investment ttm profitability gross margin ttm  ebit margin ttm  profit margin ttm  historical financial information is provided by morningstar inc prothena corporation plc makes no representations or warranties with respect to the information contained herein and takes no responsibility for supplementing updating or correcting any such information mil  millions  rtma  rolling three month average ttm  trailing twelve months  mrq  most recent quarter pricing and volume data as of  facebook google linkedin twitter email rss close scroll to top prta key statistics  prothena corp plc financial ratios  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close prothena corp plc nasdaq prta go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus prothena corp plc after hours  quotes are delayed by  min jul    pm prta quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description prothena corp plc is a clinical stage biotechnology company which engages in the discovery development and commercialization of novel antibodies its antibodybased product candidates target a number of potential indications including al amyloidosis neod parkinsons disease and related syn prothena corp plc is a clinical stage biotechnology company which engages in the discovery development and commercialization of novel antibodies its antibodybased product candidates target a number of potential indications including al amyloidosis neod parkinsons disease and related synucleinopathies prx inflammatory diseases including psoriasis psoriatic arthritis prx and attr amyloidosis prx the company was founded on december   and is headquartered in dun laoghaire ireland valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title dr gene g kinney   president chief executive officer  director mr tran b nguyen   chief financial officer dr wagner zago   chief scientific officer dr sarah noonberg   chief medical officer mr david b mcninch   chief commercial officer insider actions – purchase – sale  – number of transactions  date name shares transaction value  christopher s henney director    disposition at  per share   karin l walker see remarks    disposition at  per share   karin l walker see remarks    disposition at  per share   christopher s henney director    derivativenonderivative trans at  per share   karin l walker see remarks    derivativenonderivative trans at  per share   dennis j selkoe director    disposition at  per share   dennis j selkoe director    disposition at  per share   dennis j selkoe director    derivativenonderivative trans at  per share   karin l walker see remarks    disposition at  per share   karin l walker see remarks    disposition at  per share   karin l walker see remarks    disposition at  per share   karin l walker see remarks    derivativenonderivative trans at  per share   karin l walker see remarks    derivativenonderivative trans at  per share   dennis j selkoe director    disposition at  per share   dennis j selkoe director    derivativenonderivative trans at  per share   tran b nguyen chief financial officer    acquisition at  per share   dennis j selkoe director    disposition at  per share   gene g kinney president and ceo director    disposition at  per share   gene g kinney president and ceo director    disposition at  per share   arthur william homan chief legal officer    disposition at  per share   dennis j selkoe director    derivativenonderivative trans at  per share   gene g kinney president and ceo director    derivativenonderivative trans at  per share   arthur william homan chief legal officer    derivativenonderivative trans at  per share   gene g kinney president and ceo director    disposition at  per share   gene g kinney president and ceo director    derivativenonderivative trans at  per share   christopher s henney director    disposition at  per share   christopher s henney director    derivativenonderivative trans at  per share   christopher s henney director    disposition at  per share   christopher s henney director    derivativenonderivative trans at  per share   arthur william homan chief legal officer    disposition at  per share   arthur william homan chief legal officer    derivativenonderivative trans at  per share  newslatestcompanyusprta marketwatch news on prta charting the sp ’s bullishleaning holding pattern ahead of the fed  pm sept    michael ashbaugh charting the sp ’s bullishleaning holding pattern ahead of the fed  pm sept    michael ashbaugh prothena started at overweight with  stock price target at barclays  am may    tomi kilgore dozens of biotech companies are ‘free’ for investors’ taking  am feb    michael brush charting a gardenvariety market pullback  pm nov    michael ashbaugh charting a gardenvariety market pullback  pm nov    michael ashbaugh sp  holds major support preserving the bull trend  pm june    michael ashbaugh sp  holds major support preserving the bull trend  am june    michael ashbaugh  stocks to watch  pm march    the trading deck prothena shares jump on parkinsons drug study data  pm march    wallace witkowski nike shares rise after profit beat revenue miss  pm march    wallace witkowski roche prothena ink pact on parkinsons treatments  am dec    marketwatchcom newsnonmarketwatchcompanyusprta other news on prta prothena announces midstage initiation of parkinsons drug  pm july    seeking alpha prothena slumps  on muddy waters short position doubts efficacy of lead product candidate  am june    seeking alpha prothena prta down  since earnings report can it rebound  am june    zackscom premarket analyst action  healthcare  am may    seeking alpha safety concerns with ionis inotersen makes prothena worth a look  piper  pm may    seeking alpha prothena prta q loss narrower than expected updates view  pm may    zackscom notable earnings after tuesday’s close  pm may    seeking alpha what to expect from prothena prta this earnings season  pm april    zackscom prothena prta clinical results from phase b mad study of prxrg in patients with parkinsons disease  slideshow  pm april    seeking alpha why is prothena prta up  since the last earnings report  am march    zackscom premarket analyst action  healthcare  am march    seeking alpha k prothena corp plc  am feb    edgar online  edg  q k prothena prta reports widerthanexpected loss in q  pm feb    zackscom prothenas prta ceo gene kinney on q  results  earnings call transcript  am feb    seeking alpha the zacks analyst blog highlights incyte prothena acorda therapeutics and axovant sciences  am feb    zackscom drug stocks earnings slated for feb  incy prta  more  am feb    zackscom can prothena prta pull a surprise this earnings season  pm feb    zackscom prothena grabbing at chunk of  billion io market ceo exclusive  pm jan    investors business daily  healthcare stocks that will cripple your portfolio  pm jan    investorplacecom prothena prta presents at th annual jp morgan healthcare conference  am jan    seeking alpha loading more headlines at a glance prothena corp plc adelphi plaza upper georges street dun laoghaire dublin  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue m net income m employees  annual report for prta newspressreleasecompanyusprta press releases on prta prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinsons disease  pm july    globenewswire prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinsons disease  pm july    globe newswire prothena announces appointment of wagner zago phd as chief scientific officer  am june    globenewswire prothena announces appointment of wagner zago phd as chief scientific officer  am june    globe newswire prothena announces appointment of sarah noonberg md phd as chief medical officer  pm may    globe newswire prothena announces appointment of sarah noonberg md phd as chief medical officer  pm may    globenewswire prothena reports first quarter  financial results and provides rd update  pm may    globenewswire prothena reports first quarter  financial results and provides rd update  pm may    globe newswire prothena to report first quarter  financial results on may   pm may    globenewswire prothena to report first quarter  financial results on may   pm may    globe newswire prothena to participate in the deutsche bank nd annual health care conference  pm april    globe newswire prothena to participate in the deutsche bank nd annual health care conference  pm april    globenewswire clinical results presented from prothenas phase b study of prxrg demonstrating robust antibody cns penetration and significant reduction of free serum alphasynuclein in patients with parkinsons disease  am april    globenewswire prothena corporation plc  press release  am april    globe newswire results for prothenas phase b multiple ascending dose study of prx  pm march    globe newswire results for prothenas phase b multiple ascending dose study of prxrg in patients with parkinsons disease to be presented at the th international conference on alzheimers and parkinsons diseases  pm march    globenewswire learn how to target a  return on avexis inc or get optiontrade ideas on ionis pharmaceuticals the medicines co prothena and tesaro inc or any stock you choose  am march    pr newswire  prf prothena announces pricing of public offering of  ordinary shares  am march    globe newswire prothena announces pricing of public offering of  ordinary shares  am march    globenewswire prothena announces public offering of ordinary shares  pm march    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aintel earnings have message for amd and nvidia ‘bring it on’ aamazon’s freespending ways hit earnings but don’t expect a shift to thrift amerck q januviajanumet revenue  bln vs  bln factset consensus  bln amerck q keytruda sales  mln vs  mln a year ago factset consensus  mln amerck raises  revenue outlook to  bln bln from  bln bln amerck affirms  adj eps outlook of  amerck q revenue  bln vs  bln factset consensus  bln amerck q adj eps  factset consensus  cents amerck q eps  cents vs  cents a year ago arussia retaliates to new sanctions by telling us to cut diplomats aget ready for the lessprofitable amazon that you used to know athis basic balanced index fund is beating the hedge fund averages arenault profit leaps but shares decline abelgiums inflation rate picks up pace agerman consumer prices rise faster than expected afrench economy expands  in the second quarter abig six leave border adjustment out of tax principles akids are training to be ceos and spies at these specialized summer camps aamericans are so uncomfortable asking for money that we’ve resorted to this instead aoil pauses ahead of us rig data but  weekly gain in sight loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  historic stock lookup  prothena corporation plc historic stock lookup adjusted historic prices for the week of july   date open high low close volume jul        jul        jul        jul        historic month january february march april may june july august september october november december historic day  historic year  lookup year end stock prices the historical stock information provided is for informational purposes only and is not intended for trading purposes the historical stock information is provided by mergent a third party service and prothena corporation plc does not maintain or provide information directly to this service prices display splitadjusted cost basis per share on that date facebook google linkedin twitter email rss close scroll to top investor relations  prothena corporation plc investor relations prothena corporation plc nasdaq prta is a latestage clinical biotechnology company focused on the discovery development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion our antibodybased product candidates target a number of potential indications including al amyloidosis neod parkinson’s disease and other related synucleinopathies prx inflammatory diseases including psoriasis and psoriatic arthritis prx and attr amyloidosis prx intra  mo  mo  yr press releases prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinsons disease jul   prothena announces appointment of wagner zago phd as chief scientific officer jun   view all events  presentations jefferies  global healthcare conference jun   at  am et listen to webcast ubs  global healthcare conference may   at  am et listen to webcast view all facebook google linkedin twitter email rss close scroll to top prothena corporation plc private company information  bloomberg july    am et biotechnology company overview of prothena corporation plc snapshot people company overview prothena corporation plc a latestage clinical biotechnology company focuses on the discovery development and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion it is developing antibodybased product candidates that include neod a monoclonal antibody that is in phase iii and phase iib clinical trials for the treatment of al amyloidosis prx that has completed phase ib clinical trial for treating parkinson’s disease and other related synucleinopathies prx a monoclonal antibody that is in phase ib for the treatment of psoriasis and other inflammatory diseases and prx a monoclonal antibody that is unde prothena corporation plc a latestage clinical biotechnology company focuses on the discovery development and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion it is developing antibodybased product candidates that include neod a monoclonal antibody that is in phase iii and phase iib clinical trials for the treatment of al amyloidosis prx that has completed phase ib clinical trial for treating parkinson’s disease and other related synucleinopathies prx a monoclonal antibody that is in phase ib for the treatment of psoriasis and other inflammatory diseases and prx a monoclonal antibody that is under preclinical development the company has a license development and commercialization agreement with f hoffmannla roche ltd and hoffmannla roche inc to develop and commercialize antibodies that target alphasynuclein prothena corporation plc was incorporated in  and is headquartered in dún laoghaire ireland detailed description adelphi plazaupper georges streetdún laoghaire  a tirelandfounded in  employees phone     fax     wwwprothenacom key executives for prothena corporation plc mr gene g kinney phd chief executive officer president and director age  total annual compensation k mr tran b nguyen mba chief financial officer age  total annual compensation k ms carol d karp chief regulatory officer age  total annual compensation k mr arthur w homan jd chief legal officer age  total annual compensation k compensation as of fiscal year  prothena corporation plc key developments prothena corporation plc announces initiation of phase  pasadena study of prxrg in patients with early parkinson’s disease jul   prothena corporation plc announced that the first patient has been enrolled in pasadena a global phase  study of prxrg in patients with early parkinson’s disease prxrg is an antialphasynuclein antibody under investigation as a diseasemodifying treatment for parkinson’s disease and is the focus of a worldwide collaboration between prothena and roche the start of the study triggered a  million milestone from roche to prothena which was earned in the second quarter of  prothena had previously received  million in upfront and development milestone payments pasadena is a twopart phase  clinical study in early parkinson’s disease patients that is being conducted by roche part  is a randomized doubleblind placebocontrolled threearm study designed to enroll approximately  patients to evaluate the efficacy and safety of prxrg in patients over  weeks in part  patients will be randomized on a  basis to receive one of two active doses  mg or  mg of prxrg or placebo via intravenous infusion once every  weeks eligible patients must not be on dopaminergic therapy and must not be expected to require dopaminergic therapy for at least  weeks part  of the study is a week blinded extension phase in which patients from the placebo arm of the study will be rerandomized onto one of two active doses on a  basis so that all participants will be on active treatment patients who were originally randomized to an active dose will continue at that dose level for the additional  weeks in part  patients will be allowed to use concomitant dopaminergic therapy any patient who medically requires initiation of dopaminergic therapy during part  will have their subsequent data censored for the primary endpoint analysis the primary endpoint of this study is the comparison of change from baseline in the movement disorder societyunified parkinsons disease rating scale mdsupdrs total score sections   and  at the completion of part  week  in each treatment group vs the placebo group the study is designed with  power and a onesided alpha of  to detect a  relative between group reduction from baseline to week  a prespecified exploratory analysis will compare the results of the two pooled treatment arms vs placebo key secondary endpoints include safety tolerability and datspect imaging prothena corporation plc announces appointment of wagner zago as chief scientific officer jun   prothena corporation plc announced the appointment of wagner zago phd as chief scientific officer cso dr zago who has been prothena’s head of research since  will have responsibility for defining and executing the company’s research strategy and advancing the company’s drug discovery pipeline dr zago joined prothena in  when the company was founded after spinning out of elan pharmaceuticals first as head of pharmacology and neuropathology and more recently as vice president head of research during his tenure at prothena he has led teams that have built a strong discovery pipeline and advanced four programs based on novel mechanisms through discovery and preclinical development into the clinic prothena corporation plc announces management changes may   prothena corporation plc announced the appointment of sarah noonberg md phd as chief medical officer dr noonberg will have key responsibilities to define and advance prothenas product pipeline and for leadership of prothenas clinical and medical organizations she succeeds martin koller md whose planned retirement from prothena at the end of  was previously announced dr noonberg joins prothena after serving as group vice president and head of global clinical development at biomarin pharmaceuticals where she was responsible for development strategy and execution across a diverse clinical portfolio similar private companies by industry company name region alexo therapeutics ltd europe algae health ltd europe alimentary health limited europe altratech limited europe artugen therapeutics limited europe recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact prothena corporation plc please visit wwwprothenacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry prta stock price  prothena corp plc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y djia f    sp f    nasdaq f    gold    silver    crude oil    sp  movers adp  tsco  vz  orly  ca  jci  ffiv  xl  latest newsall times eastern a updated intel earnings have message for amd and nvidia ‘bring it on’ a updated amazon’s freespending ways hit earnings but don’t expect a shift to thrift a merck q januviajanumet revenue  bln vs  bln factset consensus  bln a merck q keytruda sales  mln vs  mln a year ago factset consensus  mln a merck raises  revenue outlook to  bln bln from  bln bln a merck affirms  adj eps outlook of  a merck q revenue  bln vs  bln factset consensus  bln a merck q adj eps  factset consensus  cents a merck q eps  cents vs  cents a year ago a updated russia retaliates to new sanctions by telling us to cut diplomats to be replaced home investing quotes stocks united states prta overview compare quotes stock screener earnings calendar sectors nasdaq prta us nasdaq join td ameritrade find a broker prothena corp plc watchlist createprtaalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones charting the sp ’s bullishleaning holding pattern ahead of the fed sep   at  pm et by michael ashbaugh charting the sp ’s bullishleaning holding pattern ahead of the fed sep   at  pm et by michael ashbaugh prothena started at overweight with  stock price target at barclays may   at  am et by tomi kilgore opinion dozens of biotech companies are ‘free’ for investors’ taking feb   at  am et by michael brush charting a gardenvariety market pullback nov   at  pm et by michael ashbaugh charting a gardenvariety market pullback nov   at  am et by michael ashbaugh sp  holds major support preserving the bull trend jun   at  pm et by michael ashbaugh sp  holds major support preserving the bull trend jun   at  am et by michael ashbaugh  stocks to watch mar   at  pm et by harry boxer corrected prothena shares jump on parkinsons drug study data mar   at  pm et by wallace witkowski nike shares rise after profit beat revenue miss mar   at  pm et by wallace witkowski roche prothena ink pact on parkinsons treatments dec   at  am et stocks to watch macerich darden restaurants tiffany mar   at  am et on the wall street journal prothena reports positive results for parkinson’s treatment in earlystage study mar   at  pm et on the wall street journal rbc is in the lead going into the turn jul   at  am et on barrons prothena revved up by roche deal dec   at  pm et on barrons stocks to watch lululemon ciena facebook dec   at  am et on the wall street journal cfo moves par technology ocz technology group prothena mar   at  pm et on the wall street journal recent news other news press releases prothena announces midstage initiation of parkinsons drug prothena announces midstage initiation of parkinsons drug jul   at  pm et on seeking alpha muddy waters shorts prothena on doubts of drug candidates efficacy muddy waters shorts prothena on doubts of drug candidates efficacy jun   at  pm et on benzingacom prothena slumps  on muddy waters short position doubts efficacy of lead product candidate prothena slumps  on muddy waters short position doubts efficacy of lead product candidate jun   at  am et on seeking alpha prothena prta down  since earnings report can it rebound prothena prta reported earnings  days ago whats next for the stock we take a look at earnings estimates for some clues jun   at  am et on zackscom premarket analyst action  healthcare premarket analyst action  healthcare may   at  am et on seeking alpha prothena prta q loss narrower than expected updates view prothena corporation plc prta reported a loss of  cents per share in the first quarter of  wider than the yearago loss of  cents may   at  pm et on zackscom safety concerns with ionis inotersen makes prothena worth a look  piper safety concerns with ionis inotersen makes prothena worth a look  piper may   at  pm et on seeking alpha notable earnings after tuesday’s close notable earnings after tuesday’s close may   at  pm et on seeking alpha what to expect from prothena prta this earnings season apr   at  pm et on zackscom prothena prta clinical results from phase b mad study of prxrg in patients with parkinsons disease  slideshow apr   at  pm et on seeking alpha why is prothena prta up  since the last earnings report mar   at  am et on zackscom premarket analyst action  healthcare mar   at  am et on seeking alpha k prothena corp plc feb   at  am et on edgar online  edg  q k prothena prta reports widerthanexpected loss in q feb   at  pm et on zackscom prothenas prta ceo gene kinney on q  results  earnings call transcript feb   at  am et on seeking alpha the zacks analyst blog highlights incyte prothena acorda therapeutics and axovant sciences feb   at  am et on zackscom drug stocks earnings slated for feb  incy prta  more feb   at  am et on zackscom can prothena prta pull a surprise this earnings season feb   at  pm et on zackscom prothena grabbing at chunk of  billion io market ceo exclusive jan   at  pm et on investors business daily  healthcare stocks that will cripple your portfolio jan   at  pm et on investorplacecom prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinsons disease prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinsons disease jul   at  pm et on globe newswire prothena announces appointment of wagner zago phd as chief scientific officer prothena announces appointment of wagner zago phd as chief scientific officer jun   at  am et on globenewswire prothena announces appointment of wagner zago phd as chief scientific officer prothena announces appointment of wagner zago phd as chief scientific officer jun   at  am et on globe newswire prothena announces appointment of sarah noonberg md phd as chief medical officer prothena announces appointment of sarah noonberg md phd as chief medical officer may   at  pm et on globenewswire prothena announces appointment of sarah noonberg md phd as chief medical officer prothena announces appointment of sarah noonberg md phd as chief medical officer may   at  pm et on globe newswire prothena reports first quarter  financial results and provides rd update prothena reports first quarter  financial results and provides rd update may   at  pm et on globe newswire prothena to report first quarter  financial results on may  prothena to report first quarter  financial results on may  may   at  pm et on globenewswire prothena to report first quarter  financial results on may  prothena to report first quarter  financial results on may  may   at  pm et on globe newswire prothena to participate in the deutsche bank nd annual health care conference apr   at  pm et on globe newswire prothena to participate in the deutsche bank nd annual health care conference apr   at  pm et on globenewswire clinical results presented from prothenas phase b study of prxrg demonstrating robust antibody cns penetration and significant reduction of free serum alphasynuclein in patients with parkinsons disease apr   at  am et on globenewswire prothena corporation plc  press release apr   at  am et on globe newswire results for prothenas phase b multiple ascending dose study of prx mar   at  pm et on globe newswire results for prothenas phase b multiple ascending dose study of prxrg in patients with parkinsons disease to be presented at the th international conference on alzheimers and parkinsons diseases mar   at  pm et on globenewswire learn how to target a  return on avexis inc or get optiontrade ideas on ionis pharmaceuticals the medicines co prothena and tesaro inc or any stock you choose mar   at  am et on pr newswire  prf prothena announces pricing of public offering of  ordinary shares mar   at  am et on globe newswire prothena announces pricing of public offering of  ordinary shares mar   at  am et on globenewswire prothena corporation plc  prothena announces public offering of ordinary shares mar   at  pm et on globe newswire prothena announces public offering of ordinary shares mar   at  pm et on globenewswire prothena reports fourth quarter and full year  financial results and provides financial guidance and rd update feb   at  pm et on globenewswire prothena corp plc prothena corp plc is a clinical stage biotechnology company which engages in the discovery development and commercialization of novel antibodies its antibodybased product candidates target a number of potential indications including al amyloidosis neod parkinsons disease and related synucleinopathies prx inflammatory diseases including psoriasis psoriatic arthritis prx and attr amyloidosis prx the company was founded on december   and is headquartered in dun laoghaire ireland see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top initiations may   at  am et on benzingacom heres why theres been a rush of biotech offerings jan   at  am et on benzingacom ubs biotech will continue to outperform in  sep   at  pm et on benzingacom competitors name chg  market cap shire plc adr  b alnylam pharmaceuticals inc  b amarin corp plc adr  b alkermes plc  b mallinckrodt plc  b competitor data provided by partner content trending tickers powered by amzn  spy  uvxy  aapl  fslr  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » prothena corp plc  nasdaqprta  stock quote  news  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street prothena corp plc prta follow  nasdaq  health care jul    pm edt prev close  day lowhigh     wk lowhigh    avg volume k exchange nasdaq shares outstanding m market cap b eps  pe ratio na div  yield na na trade with jim cramer  days free latest news these are the best growth stocks right now in biotech prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinsons disease  stocks you probably never heard of could catch fire soon six charts showing signs of smart money footprints jun    am edt prothena announces appointment of wagner zago phd as chief scientific officer jun    am edt prothena announces appointment of sarah noonberg md phd as chief medical officer may    pm edt prothena reports first quarter  financial results and provides rd update may    pm edt prothena to report first quarter  financial results on may  may    pm edt prothena to participate in the deutsche bank nd annual health care conference apr    pm edt clinical results presented from prothenas phase b study of prxrg demonstrating robust antibody cns penetration and significant reduction of free serum alphasynuclein in patients with parkinsons disease apr    am edt results for prothenas phase b multiple ascending dose study of prxrg in patients with parkinsons disease to be presented at the th¿ international conference on alzheimers and parkinsons diseases mar    pm est prothena raises m to bring antiorgan failure drug to market the biotech company plans to commercialize its treatment for al amyloidosis a disease that causes protein to build up in the blood mar    pm est biotech premarket movers karyopharm lexicon prothena karyopharm therapeutics falls  lexicon rises on drug approval mar    am est prothena announces pricing of public offering of  ordinary shares mar    am est prothena announces public offering of ordinary shares mar    pm est prothena reports fourth quarter and full year  financial results and provides financial guidance and rd update feb    pm est prothena to participate in the leerink partners th annual global healthcare conference feb    pm est prothena to report fourth quarter and full year  financial results and host webcast conference call on february  feb    pm est prothena to participate in the jp morgan healthcare conference jan    pm est prothena announces appointment of chief regulatory officer dec    pm est firstinhuman assessment of prx prothenas antialpha synuclein antibody for parkinsons disease published in movement disorders journal data previously presented in  at th international congress of parkinsons disease and movement disorders dec    pm est prothena reports results from phase b study of prx demonstrating robust antibody cns penetration and significant reduction of free serum alphasynuclein in patients with parkinsons disease nov    pm est data for prothenas neod to be presented at the th annual american society of hematology meeting nov    am edt prothena reports third quarter  financial results and provides rd update nov    pm edt prothena to report third quarter  financial results on november  oct    pm edt prothena announces appointment of dr gene g kinney as president chief executive officer and director oct    am edt in memoriam  friend scientific innovator and leader dr dale b schenk has passed away sep    pm edt prothena outlines phase  development strategy for prx sep    pm edt prothena announces president and ceo dr dale b schenk to take medical leave sep    pm edt prothena to host update on prx phase  development strategy sep    pm edt prothena announces appointment of gene g kinney as chief operating officer sep    pm edt next load more quant rating on  pm edt  d sell get the prta report here from our partners prothena initiated with a buy at jefferies the fly prothena announces midstage initiation of parkinsons drug seekingalpha feared short seller carson blocks next target is this biotech stock cnbc prothena claws back from bearish report from short seller down  seekingalpha prothena slumps  on muddy waters short position doubts efficacy of lead product candidate seekingalpha premarket analyst action  healthcare seekingalpha prothena initiated with a buy at btig the fly new medical chief at prothena seekingalpha safety concerns with ionis inotersen makes prothena worth a look  piper seekingalpha piper jaffray sees positive readthrough for prothena from ionis data the fly prothena has positive read through from ionis safety issues says suntrust the fly prothena eps of  seekingalpha notable earnings after tuesday’s close seekingalpha prothena initiated with an overweight at cantor the fly prothena initiated with an overweight at piper jaffray the fly thestreet quant rating d sell get the prta report here trending amazon falls obamacare repeal fails   things you must know before the market opens amazons shock earnings show that its cashing in on wall streets goodwill these are our  biggest stories on amazons bizarre earnings whiff teslas model  arrives on friday  heres everything you need to know about this overhyped ride ftc seen as set to block rite aid deal advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising prtanasdaq gs stock quote  prothena corp plc  bloomberg markets error could not add to watchlist x  watchlist prothena corp plc prtaus nasdaq gs usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  dgapadhoc bb biotech ag tailwind for biotech investors  prothena corporation plc prothena announces initiation of phase  pasadena study of prxrg in patients with early  prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinson’s disease  multiple sclerosis drugs and therapeutic pipeline review h  research available at rnr market research  prothena corporation plc prothena announces appointment of wagner zago phd as chief scientific officer  prothena announces appointment of wagner zago phd as chief scientific officer  prothena corporation plc prothena announces appointment of sarah noonberg md phd as chief medical officer  prothena announces appointment of sarah noonberg md phd as chief medical officer  prothena corporation plc prothena reports first quarter  financial results and provides rd update  prothena reports first quarter  financial results and provides rd update there are currently no press releases for this ticker please check back later profile prothena corporation plc is a biotechnology company the company focuses on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding and cell adhesion address adelphi plazaupper georges street dun laodublin a tireland phone  website wwwprothenacom executives board members gene g kinney presidentceo tran b nguyen cfoinvestor relations karin l walker chief acctg officercontroller tara nickerson chief business officer sarah noonberg chief medical officer show more facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     prothena corporation plc  ordi nasdaqprta sees unusual trading volume in its shares  highlight press highlight pressbreaking tech news entertainment mortgages and more prothena corporation plc – ordi nasdaqprta sees unusual trading volume in its shares july   by clarence martin tweet        advertisement trading was heavy with k shares changing hands by the end of trading on friday volume was up  over the stocks average daily volume here is the rundown on market activity for prothena corporation plc – ordi nasdaqprta director christopher s henney sold  shares at an average price of  on july th the director now owns  of the stock as reported to the sec karin l walker see remarks let go of  worth of shares at an average price of  on mon the th walker now owns  of stock as recorded in a recent form  sec filing the following firms have also recently changed their position in prta aperio group llc augmented its ownership by buying  shares an increase of  aperio group llc now controls  shares worth  the value of the position overall is up by  as of the end of the quarter fisher asset management llc had acquired a total of  shares growing its stake by  the value of the investment in prta went from  to  a change of  quarter over quarter as of quarter end creative planning had bought  shares growing its position  the value of the company’s investment in prothena corporation plc – ordi increased from  to  increasing  for the reporting period bank of montreal can grew its position by buying  shares an increase of  from  to  bank of montreal can owns  shares with a value of  the total value of its holdings increased  on july   jefferies initiated coverage on the stock with a rating of “buy” equity analyst btig research started covering the stock by announcing an initial rating of “buy” on november  analysts at deutsche bank began coverage of prta with an initial rating of “buy” barclays starting coverage on the stock setting a rating of “overweight” and establishing a price target of  equity analyst credit suisse initiated coverage on prta giving it an initial rating of “outperform” and projecting a price target of  on june  analysts at ubs added prta to its research portfolio giving it an initial rating of “buy” and setting a price target of  the company is trading down since yesterday’s close of  shares of the company are trading at  slightly over  the  day moving average and which is just over the  day moving average of  the  day moving average was up  and the  day average was up  as of the latest earnings report the eps was  and is expected to be  for the current year with  shares presently outstanding next quarter’s eps is expected be  and the next full year eps is anticipated to be  prothena corporation public limited company launched on september   is a global biotechnology company the company is focused on the discovery development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion the business’s clinical pipeline of antibodybased product candidates targets a range of indications including amyloid lightchain al amyloidosis neod parkinson’s disease and other related synucleinopathies prx and inflammatory diseases including psoriasis and psoriatic arthritis prx and attr amyloidosis prx the company has generated monoclonal antibodies that selectively bind to amyloidogenic diseased forms of the transthyretin ttrmediated amyloidosis attr protein the business’s pipeline also includes late discoverystage programs for which the company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion         advertisement         advertisement mortgage rate updates thursday’s rates for home mortgages at citizens suntrust jul   … read moremortgage rate summary for chase bank hsbc jul  chase bankthe benchmark  year frms start at  at chase bank nysejpm and apr of … read morepnc bank bank of america today’s mortgage rates jul   … read morehome loans quicken td bank mortgage rates jul  quicken loansthe benchmark  year fixed rate loan interest rates are published at  at … read more sports lonzo ball’s latest footwear has well and truly floppedhere’s a question – would all the social media hype and celebrity endorsements in the world encourage you to spend  on a pair of basketball … read moresuper bowl winners to pocket  per player – taxfreeit’s long been known that the tax returns of professional athletes are just about as complex as it gets this is because not only do they have to pay … read more top news business technology sports entertainment life mortgages also in the news… about us writers advertise with us contact us reuters technology news xiaomi gains new  billion loan to drive retail push expansion overseasamazon plows ahead with high sales and spending profit plungeschinas baidu profit jumps as focus on mobile ai narrows highlight press is a participant in the amazon services llc associates program an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to amazoncom prothena corporation plc – ordi nasdaqprta traded  above its  day average finance dailydaily markets commodities personal finance and economic newsprothena corporation plc – ordi nasdaqprta traded  above its  day average july   by ted blackburn tweet         advertisement it is trading at  which is slightly above  the stock’s  day moving average and a tad above the  day moving average of  the  day moving average went up  or  and the  day average moved up  trading volume for prothena corporation plc – ordi was k on tuesday trading volume was down  under the stocks average daily volume there has been some selling insider activity on prothena corporation plc – ordi nasdaqprta recently christopher s henney director disclosed the sale of  shares of prta stock the shares were sold on july th for an average price of  henney now owns  of the stock per the form  sec filing karin l walker see remarks sold  worth of shares at an average price of  on mon the th that brings walker’s holdings to  as recorded in a recent form  sec filing these funds have also shifted positions in prta as of the end of the quarter aperio group llc had bought  shares growing its holdings by  the value of the company’s investment in prothena corporation plc – ordi increased from  to  a change of  quarter over quarter as of quarter end fisher asset management llc had acquired a total of  shares growing its stake by  the value of the investment in prta went from  to  increasing  quarter to quarter creative planning grew its stake by buying  shares an increase of  as of  creative planning owns  shares worth  the total value of its holdings increased  as of quarter end bank of montreal can had acquired  shares growing its position  the value of the total investment in prothena corporation plc – ordi went from  to  a change of  for the reporting period        advertisement equity analyst jefferies issued its first research report on the stock by announcing an initial rating of “buy” btig research initiated coverage with a rating of “buy” on november  analysts at deutsche bank initiated coverage on prta giving it an initial rating of “buy” on may   barclays started coverage setting a rating of “overweight” and a price target of  equity analyst credit suisse began coverage of the stock with an initial rating of “outperform” and projecting a price target of  on june  analysts at ubs added the stock to its research portfolio with a rating of “buy” and setting a price target of  the company is trading unchanged since yesterday’s close of  as of the last earnings report the eps was  and is estimated to be  for the current year with  shares presently outstanding next quarter’s eps is estimated at  and the next full year eps is anticipated to be  prothena corporation public limited company launched on september   is a global biotechnology company the company is focused on the discovery development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion the business’s clinical pipeline of antibodybased product candidates targets a range of indications including amyloid lightchain al amyloidosis neod parkinson’s disease and other related synucleinopathies prx and inflammatory diseases including psoriasis and psoriatic arthritis prx and attr amyloidosis prx the company has generated monoclonal antibodies that selectively bind to amyloidogenic diseased forms of the transthyretin ttrmediated amyloidosis attr protein the business’s pipeline also includes late discoverystage programs for which the company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion         advertisement tweetrevenue generating websites cdw corporation nasdaqcdw experiences lighter than average trading volumecherokee inc nasdaqchke sees significantly lower trading volumecanadian national railway compa nysecni sees unusual trading volume in its sharescapitol federal financial inc nasdaqcffn experiences light trading volumecelanese corporation celanese c nysece experiences light trading volumechina eastern airlines corporat nysecea experiences lighter than usual trading volumebaidu inc – american deposita nasdaqbidu traded significantly above its  day average markets economy peertopeer loans growing in popularity among consumersincrease in young american adults not owning credit cards for various reasons credit  loans suntrust citizens mortgage rate wrap up jul   … read more categories breaking technology auto health personal finance economy mortgage about fi daily home staff privacy policy contact us accessibility terms of use reuters business news amazon plows ahead with high sales and spending profit plungeswells fargo to refund  million to customers hit by car loan insuranceus coal exports soar in boost to trump energy agenda data showsdigital currency startups shrug off sec warning on fund raisingasian shares pull back after us techs knocked off highs prothena – harnessing the power of the immune system to fight progressive diseases harnessing the power of the immune system to fight progressive disease learn more careerspartneringinvestorsabout usnewscontact menuabout us management board of directors partnering our history pipeline neod prx prx prx publications investors press releases events  presentations financials  filings sec filings quarterly results key ratios irish statutory financial statements corporate governance committee composition stock information historic stock lookup investment calculator analyst coverage patients amyloidosis parkinson’s disease inflammatory disease  psoriasis  psoriatic arthritis clinical trials compassionate use careers core values compensation and benefits opportunities public house contact us headquarters prothena corporation plc adelphi plaza upper george’s street dún laoghaire co dublin a t ireland information tel     fax     email infoprothenacom scroll to top careers – prothena careersprothena’s success is driven by our people we are dedicated to attracting individuals who share our vision to improve human health by putting patients first but it’s not just about what we do at prothena it’s how we do it that’s why we hire creative and courageous individuals who support one another and are not afraid to try new ideas our culture reflects our core values creative – in all that we do courageous – driven to succeed and selfless – for the greater good these values are brought to life every day by the following characteristics our core values creative – in all that we do we have a culture that fosters creativity because we understand that being creative motivates employees to engage completely and take ownership and pride in their work we recognize creativity is a key to new ideas and innovation selfless – for the greater good in order to achieve our vision of creating novel protein immunotherapies to transform patients’ lives we must also be selfless putting the unmet needs of patients first is the driving force behind our efforts at prothena courageous – driven to succeed prothena employees must also be courageous we believe that having the courage to trust in one’s own abilities take on challenges and try new approaches equates to success humor – enjoy the journey we are passionate about our unwavering commitment to develop innovative new therapies for patients in science where obstacles are common we believe that appreciating humor in the daytoday is an indispensable advantage that allows us to embrace and tackle the challenges that we face along our complex journey the progress we have made as a company reflects our core values of creativity courage and selflessness seen in each of our employees for more on prothena’s culture read the recent article “does size kill culture prothena doesn’t think so” by kevin hickey vp human resources our passion is the patient we’re working to develop new medicines to fundamentally alter the course of progressive diseases cuttingedge science is what we do “triedandtrue” won’t produce breakthroughs we challenge ourselves to target the root causes of many serious diseases to create treatments that are truly disease modifying we embrace creativity and risktaking practice intelligent risktaking to forge into uncharted scientific territory because that’s what innovation requires the team comes first we’re in this together and everyone contributes toward the common goal of helping patients collaboration is key no one can do it alone we believe in collaboration you see it in all we do starting with how we communicate and work together we’re in it for the long haul it’s true we have ambitious goals we’re driven to succeed and believe in trying new approaches we love what we do we celebrate our successes—the big ones the little ones and everything in between compensation and benefits prothena’s future success lies in the ability to attract and retain great employees we recognize strong individual performance and reward it accordingly with marketcompetitive salaries and cash and equity incentive compensation plans in addition our comprehensive benefits program is designed to meet the personal needs of our employees by offering choice and flexibility we offer highly competitive benefits across health  wellness financial wellbeing and worklife balance categories and invite you to find out more about current opportunities in our south san francisco california dublin ireland zug switzerland and field locations opportunitiesplease explore current career opportunities connect with us via linkedin or contact us directly at careersprothenacom job openings prothena is an equal opportunity employer and does not discriminate on the basis of actual or perceived race color national origin ancestry sex gender gender identity pregnancy childbirth or related medical condition religious creed physical disability mental disability age medical condition marital status sexual orientation or any other characteristic protected by federal state or local law menuabout us management board of directors partnering our history pipeline neod prx prx prx publications investors press releases events  presentations financials  filings sec filings quarterly results key ratios irish statutory financial statements corporate governance committee composition stock information historic stock lookup investment calculator analyst coverage patients amyloidosis parkinson’s disease inflammatory disease  psoriasis  psoriatic arthritis clinical trials compassionate use careers core values compensation and benefits opportunities public house contact us headquarters prothena corporation plc adelphi plaza upper george’s street dún laoghaire co dublin a t ireland information tel     fax     email infoprothenacom scroll to top corporate governance  prothena corporation plc corporate governance the board of directors of prothena corporation plc the company sets high standards for the companys employees officers and directors implicit in this philosophy is the importance of sound corporate governance and compliance with applicable laws and ethical standards  title view audit committee charter pdf  kb add to briefcase file is in briefcase compensation committee charter pdf  kb add to briefcase file is in briefcase nominating and corporate governance committee charter pdf  kb add to briefcase file is in briefcase corporate governance guidelines pdf  kb add to briefcase file is in briefcase code of conduct pdf  kb add to briefcase file is in briefcase  add file to briefcase facebook google linkedin twitter email rss close scroll to top prta  stock quote for prothena corp plc  msn money msn back to msn home money web search sign in change language  content américa latina español argentina español australia english belgië nederlands belgique français brasil português canada english canada français chile español colombia español danmark dansk deutschland deutsch españa español france français india english indonesia bahasa indonesia ireland english italia italiano malaysia english méxico español nederland nederlands new zealand english norge norsk bokmål österreich deutsch perú español philippines english polska polski portugal português schweiz deutsch singapore english south africa english suisse français suomi suomi sverige svenska türkiye türkçe united arab emirates english united kingdom english united states english united states español venezuela español việt nam tiếng việt ελλάδα ελληνικά россия pусский ישראל עברית‏ الإمارات العربية المتحدة العربية‏ المملكة العربية السعودية العربية‏ مصر العربية‏ ไทย ไทย 한국 한국어      語   switch to latino español feedback help adchoices prothena corp plc nasdaq prta us markets closed adchoices  ▼   after hours     july    pm edt delayed  minutes nasdaq currency in usd save summary financials analysis options ownership company history related open  previous close  volume avg k k days range  wk range  market cap b dividend rate  yield  beta  shares outstanding m pe ratio eps  recent news commit to purchase prothena corp at  earn  annualized using options nasdaq  prothena corp prta commences phase  pasadena study of prxrg in patients with early parkinson’s disease streetinsider  prothena shares drop as short seller muddy waters attacks bloomberg  amyloidosis pipeline drugs and therapeutics development market h  illuminated by new report whatech  days ago podcast what this biotech discovered before after ceos death the business journal  days ago prothena corporation plc prta breaks into new week high on july  session equities  days ago h amyloidosis pipeline overview of market companies and drug profile report  medgadget  palo alto investors has lifted prothena plc prta holding by  million central securities has  sentiment thorold news  amyloidosis pipeline drugs and therapeutics development progress  medgadget  westbury bancorp wbb reaches  formed hs redmile group lifted its molina healthcare moh position the bibey post   top growth stocks in biotech right now biospacecom   top growth stocks in biotech right now biospacecom  as middleby corp midd share price declined shareholder oak ridge investments llc has lowered by  million its holding presstelegraphcom  prothena corp prta is rising as phase  study of prxrg begins realtime business news  prothena corporation plc prta moves lower on volume spike for july  equities  arry working its way be all ears for auris bgne inks deal with celg finanzen   eps expected for simulations plus inc slp opaleye management boosted prothena plc prta stake by  million the bibey post  arry working its way be all ears for auris bgne inks deal with celg marketsinsidercom  adchoices adchoices adchoices markets dow dow ▲    last updated time   pm edt markets nasdaq nasdaq ▼    ftse  ftse  ▼    nyse composite nyse composite ▼    adchoices feedback send feedback provide feedback report a problem we appreciate your input select a category im having problems with top destinations im having issues searching im having problems with featured apps i see an error in the content other how we can improve please give an overall site rating submit close privacy statement help help  support investor relations  prothena corporation plc investor relations prothena corporation plc nasdaq prta is a latestage clinical biotechnology company focused on the discovery development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion our antibodybased product candidates target a number of potential indications including al amyloidosis neod parkinson’s disease and other related synucleinopathies prx inflammatory diseases including psoriasis and psoriatic arthritis prx and attr amyloidosis prx intra  mo  mo  yr press releases prothena announces initiation of phase  pasadena study of prxrg in patients with early parkinsons disease jul   prothena announces appointment of wagner zago phd as chief scientific officer jun   view all events  presentations jefferies  global healthcare conference jun   at  am et listen to webcast ubs  global healthcare conference may   at  am et listen to webcast view all facebook google linkedin twitter email rss close scroll to top contact us  prothena corporation plc contact us please submit your question using the form below contact form  indicates required field name email subject comments listen to audio version type in number submit comment facebook google linkedin twitter email rss close scroll to top